Biotech entity
Anthony Fauci is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 144-day span, the pace is roughly 0.1 stories per week. Source depth averages 2 original sources per story, versus 3.9 across the same-window beat baseline.
Last mentioned: Jul 31, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Anthony Fauci is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Across a 144-day span, the pace is roughly 0.1 stories per week. Source depth averages 2 original sources per story, versus 3.9 across the same-window beat baseline. Their average consequence score of 6 runs below the beat's 6.3 for that window. Coverage clusters in funding, which accounts for 1 of those 2, with the remainder spread across 1 other category. This profile follows 2 Biotech stories mentioning Ron Johnson across the period from March 10, 2026 to July 31, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 415 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ron Johnson. Shared-story counts are live from our verified record — not editorial picks.
Senators react
Sens. Rand Paul and Ron Johnson publicly call for legal challenges to the pardon, state-level prosecution, and full investigations into Fauci’s actions.
Gabbard releases intelligence files
Outgoing DNI Tulsi Gabbard declassifies and releases trove of documents alleging Fauci’s deception and funding of Wuhan gain-of-function research.
Initial Inquiry
The Senator's office begins requesting data on DMD drug approval timelines and internal CBER deliberations.
Investigation Announced
Sen. Ron Johnson announces a formal probe into the FDA's handling of rare disease drug applications.
Commissioner Meeting
Johnson meets with FDA Commissioner Marty Makary to discuss specific biologic therapy rejections.
Preemptive pardon granted
President Biden issues a preemptive pardon to Fauci before leaving office, covering potential federal crimes related to the pandemic.
Fauci testifies to Congress
Fauci testifies that he had no contact with intelligence agencies regarding viral research, a claim now contradicted by Gabbard's files.
Outgoing DNI Tulsi Gabbard’s intelligence release alleges Dr. Anthony Fauci directed millions in taxpayer dollars to fund dangerous bat coronavirus research at the Wuhan lab, threatening public trust and likely triggering a regulatory crackdown on gain-of-function studies across the biotech sector.
Source: fox11online.com · ktul.com
Senator Ron Johnson (R-Wisc.) has launched an investigation into the FDA's regulatory hurdles for rare disease treatments, specifically targeting biologics for Duchenne muscular dystrophy. The probe follows a direct meeting with FDA Commissioner Marty Makary and signals a significant escalation in political pressure on the agency's approval standards.
Ron Johnson is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
